[HTML][HTML] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Della Corte, M Fasano, F Ciardiello - ESMO open, 2016 - Elsevier
Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
E Santoni-Rugiu, LC Melchior, EM Urbanska… - Cancers, 2019 - mdpi.com
Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
AB Cortot, PA Jänne - European Respiratory Review, 2014 - Eur Respiratory Soc
The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins
The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
C Tomasello, C Baldessari, M Napolitano, G Orsi… - Critical reviews in …, 2018 - Elsevier
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
SK Tripathi, K Pandey… - Medicinal Research …, 2020 - Wiley Online Library
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …
Drug resistance to EGFR inhibitors in lung cancer
O Tetsu, MJ Hangauer, J Phuchareon, DW Eisele… - Chemotherapy, 2016 - karger.com
Background: The discovery of mutations in epidermal growth factor receptor (EGFR) has
dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the …
dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
相关搜索
- egfr targeted drugs
- lung cancer mechanisms of resistance
- intrinsic resistance egfr tyrosine
- egfr mutations mechanisms of resistance
- targeted therapies mechanisms of resistance
- nsclc patients mechanisms of resistance
- egfr tyrosine acquired resistance
- kinase inhibitors acquired resistance
- molecular mechanisms of resistance
- growth factor molecular mechanisms
- growth factor lung adenocarcinomas
- clinical management egfr inhibitors
- molecular mechanisms lung adenocarcinomas
- lung cancer acquired resistance
- kinase inhibitors egfr tyrosine
- lung cancer drug resistance